3 names are moving together; 67% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| TEM | Tempus AI, Inc. | Healthcare | -2.4% | Group member |
| TXG | 10x Genomics, Inc. | Healthcare | -0.3% | Group member |
| ADPT | Adaptive Biotechnologies Corpor | Healthcare | +6.8% | Most structurally connected |
Cohort
3 namesParticipation
67% this sessionObserved history
1 daily buildsFiling coverage
3/3 memberscredit / rates affecting interest expense
“Interest Expense Three Months Ended March 31, Change (in thousands, except percentages) 2026 2025 $ % Interest expense $ (2,889 ) $ (2,905 ) $ 16 (1)% The nominal decrease in interest expense was attributable to a change in our assumptions regarding the timeframe in which our Purchase Agreement will be fully repaid.”
ADPT 10-Q
product pipeline / R&D affecting expense
“These decreases were partially offset by a $3.0 million increase in materials cost resulting from increased revenue sample volume, a $1.2 million increase related to higher usage of our production laboratory to process revenue samples versus research and development samples and a $1.0 million increase in shipping and handling expenses.”
ADPT 10-Q
restructuring affecting expense
“ept percentages) 2025 2024 $ % 2025 2024 Impairment of long-lived assets $ — $ 7,205 $ (7,205 ) (100)% 0 % 17 % The $7.2 million decrease in impairment of long-lived assets expenses was attributable to the impairment of certain long-lived assets and our decision to vacate certain leased space as a result of various restructuring activities in 2024.”
ADPT 10-Q
Cross-asset confirmation is still fragile, so spillover can stall before it becomes durable.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.